Rosuvastatin (Crestor, Ezallor Sprinkle)
Other Medications · Approved since 2003
Description
Rosuvastatin is a potent HMG-CoA reductase inhibitor (statin) primarily used to lower cholesterol and prevent cardiovascular disease. In colorectal cancer treatment, rosuvastatin is being evaluated for its potential anti-cancer properties based on preclinical evidence that statins may inhibit tumor growth and metastasis. Clinical trials are examining whether rosuvastatin can improve outcomes when added to standard CRC treatment, particularly in patients with early-stage surgically resected colon cancer.
Mechanism of Action
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, blocking the conversion of HMG-CoA to mevalonate. Beyond cholesterol reduction, this inhibition disrupts the mevalonate pathway, which affects prenylation of proteins involved in cell proliferation, apoptosis, and angiogenesis. The anti-cancer effects may result from reduced protein prenylation affecting oncogenic signaling pathways including Ras and Rho family proteins.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Crestor, Ezallor Sprinkle |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS other indication |
| Administration | Oral |
| Year Approved | 2003 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.